Living donor liver transplantation
Procedureliver graft from a living donor
NCT Number: NCT04069416
The present study aims to evaluate the impact of expanding criteria beyond Milan on tumor recurrence and patient survival that will help identify the best selection criteria for HCC transplanted patients.
Looking for future studies?
Notify Me18 year–70 year
All sexes
Observational
Introduction:
HEPATOCELLULAR CARCINOMA (HCC) is the second leading cause of cancer mortality worldwide. Living donor liver transplantation (LDLT) for HCC patients has emerged as a rewarding therapy for a cure and a successful alternative where a Deceased donor liver transplantation (DDLT) program is lacking. Therefore, trials for careful expansion to Milan criteria have been adopted.
Aim of the study:
To evaluate the impact of expanding criteria beyond Milan on tumor recurrence and patient survival that will help identify the best selection criteria for HCC transplanted patients
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
liver graft from a living donor
Time frame: 3 years
Recurrence of Hepatocellular carcinoma either intra-hepatic, extra-hepatic or both
Ain Shams University
Other
Salvage Living Donor Liver Transplantation for HCC Beyond All Criteria Yield Equivalent Results to Milan Criteria in High Prevalence Young HCC Patients Country.
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01387555
Adenocarcinoma, Carcinoma
La Jolla, California, United States
View Trial DetailsNCT03817736
Adenocarcinoma, Carcinoma
Hong Kong
View Trial DetailsNCT02705105
Adenocarcinoma, Cancer
Gilbert, Arizona, United States
View Trial DetailsNCT02182687
Adenocarcinoma, Carcinoma
Burlington, Massachusetts, United States
View Trial Details